BIIB · XBRL financial data

Biogen financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BIIB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	13,445	10,982	10,173	9,836	9,676	9,891
Cost of goods and services sold	1,805	2,110	2,278	2,533	2,310	2,404
Gross profit	11,639	—	—	—	—	—
Selling, general and administrative	2,505	2,674	2,404	2,550	2,404	2,434
Operating income (loss)	4,550	2,841	—	—	—	—
Interest income	42	11	89	277	68	125
Interest expense	223	254	247	247	250	268
Other income (expense)	3	(6)	10	4	30	(25)
Income tax expense (benefit)	992	53	633	135	274	264
Net income (loss)	4,001	1,556	3,047	1,161	1,632	1,293
Earnings per share, basic USD per share	24.86	10.44	20.96	8.02	11.21	8.83
Earnings per share, diluted USD per share	24.80	10.40	20.87	7.97	11.18	8.79
Weighted average shares, basic millions of shares	161	149	145	145	146	147
Weighted average shares, diluted millions of shares	161	150	146	146	146	147

Fiscal years (BIIB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,331	2,261	3,419	1,050	2,375	3,009
Marketable securities	1,279	1,541	1,474	0	0	807
Marketable securities, non-current	772	892	706	0	0	432
Accounts receivable	1,914	1,549	1,705	1,664	1,405	1,342
Inventory	1,069	1,352	1,344	2,527	2,461	2,168
Total current assets	6,887	7,857	9,791	6,859	7,457	8,974
Property and equipment, net	3,412	3,416	3,299	3,310	3,181	3,055
Right-of-use asset	433	375	404	420	356	265
Goodwill	5,762	5,761	5,749	6,219	6,479	6,491
Total assets	24,619	23,877	24,554	26,845	28,049	29,440
Accounts payable	455	589	492	403	424	432
Total current liabilities	3,742	4,298	3,273	3,434	5,529	3,349
Lease liability, non-current	402	330	333	400	335	290
Total liabilities	13,933	12,918	11,166	12,045	11,333	11,183
Retained earnings	13,976	13,912	16,467	17,628	19,260	20,553
Total stockholders' equity	10,700	10,896	13,398	14,799	—	—
Total liabilities and equity	24,619	23,877	24,554	26,845	28,049	29,440
Common shares outstanding (cover page) millions of shares	152	147	144	145	146	147

Fiscal years (BIIB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	4,001	1,556	3,047	1,161	1,632	1,293
Stock-based compensation	198	239	254	264	291	291
Depreciation and amortization	457	488	518	495	673	780
Net cash from operating activities	4,230	3,640	1,384	1,547	2,876	2,205
Purchases of property and equipment	425	258	240	277	154	154
Net cash from investing activities	(609)	(564)	1,577	(4,101)	(799)	(1,371)
Share repurchases	6,679	1,800	750	0	0	—
Proceeds from long-term debt	2,967	0	0	997	0	1,733
Repayments of long-term debt	—	—	—	810	650	1,750
Net cash from financing activities	(5,273)	(2,086)	(1,747)	149	(684)	(302)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Biogen	1,304	2,804	641*	147.8M	—	Q3 FY26 10-QSep 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	—	Q3 FY26 10-QSep 30, 2026
INSMED	397	524	(36)*	219.4M	—	Q3 FY26 10-QSep 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
United Therapeutics	1,189	833	307*	42.6M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.